Beta Bionics
Concord, United States · Biotechnology, Healthcare · 200 employees
Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insuli
Funding history
- Series series e — $60.0M — Nov 2024
- Funding Round — $99.5M — Sep 2023
- Funding Round — $57.0M — Mar 2022
- Series series c — $57.0M — Feb 2022
- Funding Round — $63.4M — Jul 2019
Recent signals
- Jan 08, 2026: SEC 8-K (2.02): On January 8, 2026, Beta Bionics, Inc. announced its preliminary, unaudited financial results for the fourth quarter of 2025 through a press release. The announcement includes key metrics that are significant for investors, although specific financial figures were not detailed in the provided content. This filing potentially impacts investor perception and market confidence regarding the company's performance as it reflects the latest financial results and is crucial for stakeholders in understanding the company's financial health. The results are a critical indicator of the company's trajectory and are of interest to the market, contributing to ongoing assessments of its operational effectiveness and strategic planning.
- Nov 14, 2024: Raised $60.0M in Series series e
- Sep 15, 2023: Raised $99.5M
- Mar 02, 2022: Raised $57.0M
- Feb 17, 2022: Raised $57.0M in Series series c
- Jul 22, 2019: Raised $63.4M
- Sep 17, 2018: Raised $50.1M
- Dec 27, 2017: Raised $2.5M in Series seed
See plans & pricing → Track Beta Bionics’s funding, hiring, and signals — with verified contacts — on Fundz.